Effects of Biologic Therapies for Cutaneous Inflammatory Diseases in HIV-Infected Individuals: Reliable or Not?

Purpose: Patients with cutaneous inflammatory diseases often present with more aggressive and refractory clinical course in the presence of accompanying human immunodeficiency virus HIV infection. Therefore, biologic therapies may be needed to improve outcomes of these patients. The use of biologic agents in HIV positive patients is conflicting because such treatment can lead to increase the risk of infection and malignancy in already immunocompromised patients. On the other hand, some researchers have recommended that HIV management should also include the blockade of tumour necrosis factor-alpha TNF-α . We discuss the reliability and effectiveness of biologic therapies for patients with cutaneous inflammatory diseases and accompanying HIV infection.Methods: The Medline literature database search through PubMed using the key words ‘human immunodeficiency virus’, ‘cutaneous inflammatory diseases’, ‘TNF-α inhibitor’, ‘biologic therapy’, ‘biologic treatment’, ‘adalimumab’, ‘etanercept’, ‘infliximab,’ ‘ustekinumab’, and ‘rituximab’ was performed. Literature data associated with biologic therapies of cutaneous inflammatory diseases in HIV-positive patients were evaluated. Results: The literature search identified a total of 17 patients with HIV infection receiving biologic therapy for cutaneous inflammatory diseases psoriasis, psoriatic arthritis, hidradenitis suppurativa and pemphigus vulgaris from two case series and 12 case reports. Conclusion: In HIV-infected patients with severe and refractory cutaneous inflammatory diseases, biologic therapies should only be reserved for those whom HIV status is stable at baseline. Screening for tuberculosis prior to treatment and close monitoring for potential side effects are mandatory. Further multicentre randomised controlled trials about the use of biologic agents in these patient groups are necessary

Keywords:

human immunodeficiency virus, cutaneous inflammatory diseases, psoriasis and psoriatic arthritis, hidradenitis suppurativa pemphigus vulgaris, biologic therapy,

PDF

___

Fernandez JM, Fernandez AP, Lang DM. Biologic therapy in the treatment of chronic skin disorders. Immunol Allergy Clin North Am 2017;37:315–327. [CrossRef]
Fink DL, Hedley L, Miller RF. Systematic review of the efficacy and safety of biological therapy for inflammatory conditions in HIV- infected individuals. Int J STD AIDS 2017;28:110–119. [CrossRef]
Liang SJ, Zheng QY, Yang YL, Yang Y, Liu CY. Use of etanercept to treat rheumatoid arthritis in an HIV-positive patient: a case-based review. Rheumatol Int 2017;37:1207–1212. [CrossRef]
Han G. Biologics in dermatology beyond psoriasis. Cutis 2014;93:E21-E27.
Nast A, Gisondi P, Ormerod AD, et al. European S3-Guidelines on the systemic treatment of psoriasis vulgaris--update 2015--short version--EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015;29:2277–2294. [CrossRef]
Rustin MHA. Long-term safety of biologics in the treatment of moderate- to-severe plaque psoriasis: review of current data. Br J Dermatol 2012;167:3–11. [CrossRef]
Gallitano SM,McDermott L, Brar K, Lowenstein E. Use of tumor necrosis factor (TNF) inhibitors in patients with HIV/AIDS. J Am Acad Dermatol 2016;74:974–980. [CrossRef]
Husein-ElAhmed H, Fernandez-Pugnaire MA, Ruiz-Carrascosa JC. Severe hidradenitis suppurative in an HIV-positive male: use of multiple treatment modalities, including tumor necrosis factor blockade. AIDS Patient Care STDS 2011;25:507–508. [CrossRef]
Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. Int J Rheum Dis 2009;12:118–124. [CrossRef]
Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011;16:1–81. [CrossRef]
Gaylis NB. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. J Clin Rheumatol 2012;18:153–154. [CrossRef]
Habib SF, Hasan MZ, Salam I. Infliximab therapy for HIV positive Crohn’s disease: a case report. J Crohs Colitis 2009;3:302–304. [CrossRef]
Ito M,Baba M, Sato A, et al. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro. Biochem Biophys Res Commun 1989;158:307–312. [CrossRef]
Butera ST, Roberts BD, Folks TM. Ligand passing by the p75 tumour necrosis factor receptor enhances HIV-1 activation. Cytokine 1996;8:745–750. [CrossRef]
Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 2006;45:689–692. [CrossRef]
Gaube G, De Castro N, Gueguen A, et al. Treatment with adalimumab for severe immune reconstitution inflammatory syndrome in an HIV- infected patient presenting with cryptococcal meningitis. Med Mal Infect 2016;46:154–156. [CrossRef]
UNAIDS 2016 Aids Data. (cited 2017 June 15). Available from: http:// www.unaids.org/sites/default/files/media_asset/2016-AIDS-data_en.pdf
Menon K,Van Voorhees AS, Bebo BF Jr, et al. Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2010;62:291–299. [CrossRef]
Morar N, Willis-Owen SA, Maurer T, Bunker CB. HIV-associated psoriasis: pathogenesis, clinical features, and management. Lancet Infect Dis 2010;10:470–478. [CrossRef]
Zancanaro PC, McGirt LY, Mamelak AJ, Nguyen RH, Martins CR. Cutaneous manifestations of HIV in the era of highly active antiretroviral therapy: an institutional urban clinic experience. J Am Acad Dermatol 2006;54:581–588. [CrossRef]
Cedeno-Laurent F, Gómez-Flores M, Mendez N, et al. New insights into HIV-1-primary skin disorders. J Int AIDS Soc 2011;14:5. [CrossRef]
Tschachler E.. The dermatologist and the HIV/AIDS pandemic. Clin Dermatol 2014;32:286–289. [CrossRef]
Eberle FC, Brück J, Holstein J, Hirahara K, Ghoreschi K. Recent advances in understanding psoriasis [version 1; referees: 2 approved] F1000Res 2016 5:770. [CrossRef]
Aboulafia DM, Bundow D, Wilske K, Ocas UI. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. Mayo Clin Proc 2000;75:1093–1098. [CrossRef]
Bartke U, Venten I, Kreuter A, Gabbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004;150:784–786. [CrossRef]
Linardaki G, Katsarou O, Ioannidou P, Karafoulidou A, Boki K. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. J Rheumatol 2007;34:1353–1355.
Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. Joint Bone Spine 2007;74:197–200. [CrossRef]
Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008;67:710–712. [CrossRef]
Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. Arch Dermatol 2008;144:453–456. [CrossRef]
Alecsandru D, Padilla B, Izquierdo JA, Fernández-Cruz E, Sánchez- Ramón S. Severe refractory hidradenitis suppurativa in an HIV- positive patient successfully treated with infliximab. Arch Dermatol 2010;146:453–456. [CrossRef]
Paparizos V, Rallis E, Kirsten L, Kyriakis K. Ustekinumab for the treatment of HIV psoriasis. J Dermatolog Treat 2012;23:398–399. [CrossRef]
Di Lernia V, Zoboli G, Ficarelli E. Long-term management of HIV/ hepatitis C virus associated psoriasis with etanercept. Indian J Dermatol Venereol Leprol 2013;79:444. [CrossRef]
Lindsey SF, Weiss J, Lee ES, Romanelli P. Treatment of severe psoriasis and psoriatic arthritis with adalimumab in an HIV-positive patient. J Drugs Dermatol 2014;13:869–871.
Saeki H,Ito T,Hayashi M, et al. Successful treatment of ustekinumab in a severe psoriasis patient with human immunodeficiency virus infection. J Eur Acad Dermatol Venereol 2015;29:1653–1655. [CrossRef]
Polansky M, Patel N, Feldman R. Complete remission after rituximab therapy in an HIV-positive patient with pemphigus vulgaris. Br J Dermatol 2015;173:1557–1559. [CrossRef]
De Simone C, Perino F, Caldarola G, D’Agostino M, Peris K. Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports. J Int Med Res 2016;44:67–71. [CrossRef]
Soares TF, Davis MDP. Success of Goeckerman treatment in 2 patients with psoriasis not responding to biological drugs. Arch Dermatol 2007;143:950–951. [CrossRef]
Chiricozzi A, Saraceno R, Cannizzaro MV, Nistico SP, Chimenti S, Giunta A. Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir). Dermatology 2012;225:333–337. [CrossRef]
Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non- Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol 2012;87:330–333. [CrossRef]
Wyen C, Jensen B, Hentrich M, et al. Treatment of AIDS- related lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS 2012;26:457–464. [CrossRef]